Carnosine as a protective factor in diabetic nephropathy: Association with a leucine repeat of the carnosinase gene CNDP1

Diabetes

Volumn 54, Issue 8, 2005, Pages 2320-2327

  Janssen, Bart ^a   Hohenadel, Daniela ^b   Brinkkoetter, Paul ^b   Peters, Verena ^a   Rind, Nina ^a   Fischer, Christine ^a   Rychlik, Ivan ^c   Cerna, Marie ^c   Romzova, Marianna ^c   De Heer, Emile ^d   Baelde, Hans ^d   Bakker, Stephan J L ^e   Zirie, Mahmoud ^f   Rondeau, Eric ^g   Mathieson, Peter ^h   Saleem, Moin A ^h   Meyer, Jochen ^a   Koppel, Hannes ^b   Sauerhoefer, Sibylle ^b   Bartram, Claus R ^a   Nawroth, Peter ⁱ   Hammes, Hans Peter ^b   Yard, Benito A ^b   Zschocke, Johannes ^b   Van Der Woude, Fokko J ^b,j   more..

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b The Fifth Medical Clinic   (Germany)

^c CHARLES UNIVERSITY   (Czech Republic)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f HAMAD MEDICAL CORPORATION   (Qatar)

^g HÔPITAL TENON   (France)

^h SOUTHMEAD HOSPITAL   (United Kingdom)

ⁱ Third Medical Clinic   (Germany)

^j Klinikum Mannheim   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOACYLHISTIDINE DIPEPTIDASE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARNOSINE; COLLAGEN TYPE 6; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; ENZYME; FIBRONECTIN; GENE PRODUCT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LEUCINE; ORAL ANTIDIABETIC AGENT; RNA; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRINUCLEOTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CHROMOSOME 18Q; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; GENE; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MESANGIUM CELL; PODOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTECTION; REAL TIME POLYMERASE CHAIN REACTION; TRINUCLEOTIDE REPEAT;

AGED; CARNOSINE; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDASES; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; GLUCOSE; HUMANS; KIDNEY; LEUCINE; MALE; MIDDLE AGED; REPETITIVE SEQUENCES, AMINO ACID; RNA, MESSENGER; SEQUENCE ALIGNMENT;

EID: 23644445372     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.8.2320     Document Type: Article

References (46)

1. Harvey JN: Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes. Curr Opin Nephrol Hypertens 12:317-322, 2003
2. Seaquist ER, Goetz FC, Rich S, Barbosa J: Familial clustering of diabetic kidney disease: evidence of genetic susceptibility to diabetic nephropathy. N Engl J Med 320:1161-1165, 1989
3. Fava S, Hattersley AT: The role of genetic susceptibility in diabetic nephropathy: evidence from family studies. Nephrol Dial Transplant 17:1543-1546, 2002
4. Fujisawa T, Ikegami H, Kawaguchi Y, Hamada Y, Ueda H, Shintani M, Fukuda M, Ogihara T: Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 41:47-53, 1998
5. Kunz R, Bork JP, Fritsche L, Ringel J, Sharma AM: Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: a methodologic appraisal and systematic review. J Am Soc Nephrol 9:1653-1663, 1998
6. Tarnow L, Gluud C, Parving HH: Diabetic nephropathy and the insertion/ deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 13:1125-1130, 1998
7. Vardarli I, Baier LJ, Hanson RL, Akkoyun I, Fischer C, Rohmeiss P, Basci A, Bartram CR, Van Der Woude FJ, Janssen B: Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. Kidney Int 62:2176-183, 2002
8. Bowden DW, Colicigno CJ, Langefeld CD, Sale MM, Williams A, Anderson PJ, Rich SS, Freedman BI: A genome scan for diabetic nephropathy in African Americans. Kidney Int 66:1517-1526, 2004
9. Holmes DI, Wahab NA, Mason RM: Cloning and characterization of ZNF236, a glucose-regulated Kruppel-like zinc-finger gene mapping to human chromosome 18q22-q23. Genomics 60:105-109, 1999
10. Halama N, Yard-Breedijk A, Vardarli I, Akkoyun I, Yard B, Janssen B, van der Woude FJ: The Kruppel-like zinc-finger gene ZNF236 is alternatively spliced and excluded as susceptibility gene for diabetic nephropathy. Genomics 82:406-411, 2003
11. Masson E, Troncy L, Ruggiero D, Wiernsperger N, Lagarde M, Bawab SE: A-series gangliosides mediate the effects of advanced glycation end products of pericyte and mesangial cell proliferation: a common mediator for retinal and renal microangiopathy? Diabetes 54:220-227, 2005
12. Hipkiss AR, Preston JE, Himsworth DT, Worthington VC, Keown M, Michaelis J, Lawrence J, Mateen A, Allende L, Eagles PA, Abbott NJ: Pluripotent protective effects of carnosine, a naturally occurring dipeptide. Ann N Y Acad Sci 854:37-53, 1998
13. Teufel M, Saudek V, Ledig JP, Bernhardt A, Boularand S, Carreau A, Cairns NJ, Carter C, Cowley DJ, Duverger D, Ganzhorn AJ, Guenet C, Heintzelmann B, Laucher V, Sauvage C, Smirnova T: Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J Biol Chem 278:6521-6531, 2003
14. Schonherr J: Analysis of products of animal origin in feeds by determination of carnosine and related dipeptides by high-performance liquid chromatography. J Agric Food Chem 50:1945-1950, 2002
15. Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, Xing CY, Ni L, Mathieson PW, Mundel P: A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 13:630-638, 2002
16. Sraer JD, Delarue F, Hagege J, Feunteun J, Pinet F, Nguyen G, Rondeau E: Stable cell lines of T-SV40 immortalized human glomerular mesangial cells. Kidney Int 49:267-270, 1996
17. Baelde HJ, Eikmans M, Doran PP, Lappin DW, de Heer E, Bruijn JA: Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis 43:636-650, 2004
18. Eikmans M, Baelde HJ, de Heer E, Bruijn JA: Effect of age and biopsy site on extracellular matrix mRNA and protein levels in human kidney biopsies. Kidney Int 60:974-981, 2001
19. Nakai K, Kanehisa M: A knowledge base for predicting protein localization sites in eukaryotic cells. Genomics 14:897-911, 1992
20. Von Heijne G: A new method for predicting signal sequence cleavage sites. Nucleic Acid Res 14:4683-4690, 1985
21. Nerlich AG, Schleicher ED, Wiest I, Specks U, Timpl R: Immunohistochemical localization of collegen VI in diabetic glomeruli. Kidney Int 45:1648-1656, 1994
22. Borsi L, Castellani P, Risso AM, Leprini A, Zardi L: Transforming growth factor-beta regulates the splicing pattern of fibronectin messenger RNA precursor. FEBS Lett 261:175-178, 1990
23. Hohenadel D, van der Woude FJ: Gene expression in diabetic nephropathy. Curr Diab Rep 4:462-469, 2004
24. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 93:2431-2437, 1994
25. Singh R, Alavi N, Singh AK, Leehey DJ: Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 48:2066-2073, 1999
26. Ziyadeh FN, Hooffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-beta antibody in db/db mice. Proc Natl Acad Sci 97:8015-8020, 2000
27. Weigert C, Brodbeck K, Klopfer K, Haring HU, Schleicher ED: Angiotensin II induces human TGF-beta 1 promotor activation: similarity to hyperglycaemia. Diabetologia 45:890-898, 2002
28. Hill C, Flyvberg A, Rasch R, Bak M, Logan A: Transforming growth factor-beta 2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol 170:647-651, 2001
29. Hipkiss AR: Carnosine, a protective, anti-aging peptide? Int J Biochem Cell Biol 30:863-868, 1998
30. Hou WC, Chen HJ, Lin YH: Antioxidant peptides with angiotensin converting enzyme inhibitory activity and applications for angiotensin converting enzyme purification. J Agric Food Chem 51:1706-1709, 2003
31. Boldyrev A, Bulygina E, Leinsoo T, Petrushanko I, Tsubone S, Abe H: Protection of neuronal cells against reactive oxygen species by carnosine and related compounds. Comp Biochem Physiol 137:81-88, 2004
32. Hipkiss AR, Brownson C, Bertani MF, Ruiz E, Ferro A: Reaction of carnosine with aged proteins: another protective process? Ann N Y Acad Sci 959:285-294, 2002
33. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001
34. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl JMed 345:861-869, 2001
35. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, the Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
36. Fukami K, Ueda S, Yamagishi SI, Kato S, Inagaki Y, Takeuchi M, Motomiya Y, Bucala R, Iida S, Tamaki K, Imaizumi T, Cooper ME, Okuda S: AGEs activate mesangial TGF-β-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 66:2137-2147, 2004
37. Earle K, Walker J, Hill C, Viberti G: Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. N Engl JMed 326:673-677, 1992
38. Adler S: Diabetic nephropathy: linking histology, cell biology, and genetics. Kidney Int 66:2095-2106, 2004
39. McFarland GA, Holliday R: Retardation of the senescence of cultured human fibroblasts by carnosine. Exp Cell Res 212:167-175, 1994
40. Gallant S, Semyonova M, Yuneva M: Carnosine as a potential antisenescence drug. Biochemistry (Moscow) 65:1018-1021, 2000
41. Tarnow L, Rossing P, Nielsen FS, Fagerudd JA, Poirier O, Parving HH: Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 23:30-33, 2000
42. Pan JW, Hanim JR, Rothman DL, Shulman RG: Intracellular pH in human skeletal muscle by 1H NMR. Proc Natl Acad Sci U S A 85:7836-7869, 1988
43. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H, the Swedish Obese Subjects Study Scientific Group: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351:2683-2693, 2004
44. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, the Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
45. The Diabetes Control and Complication Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
46. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998